

## Supporting information

# Nickel Complexes Supported by a New Class of Fused Imidazonaphthyridine Tridentate N,N,N-Ligands for Ethylene Oligomerization and Isolation of a Key Ni-Al Intermediate

Jing Zuo,<sup>§</sup> Hongxiu Li,<sup>§</sup> Chaojie Hu,<sup>§</sup> Mei-Xin Zhao\*, and Jun Zhang\*

(<sup>§</sup>These authors have contributed equally to this work)


*Key Laboratory for Advanced Materials and Institute of Fine Chemicals, School of Chemistry  
& Molecular Engineering, East China University of Science and Technology, 130 Mei Long  
Road, Shanghai 200237, China*

## Contents

1. Synthesis of Ligands <b>L1-L5</b>	S2
2. Synthesis of Nickel Complexes <b>Ni1-Ni5</b> and <b>Ni3-Al</b>	S11
3. Oligomerization of ethylene: General procedure	S13
4. X-Ray Crystallography for Nickel Complexes	S15
5. Gas chromatograms (GC) of the oligomers	S21
6. NMR Spectra of Compounds <b>S1-S6, L1-L5</b>	S24

## 1. Synthesis of Ligands L1-L5

### 1.1 Synthesis of 8-aminoimidazo[1,2-a]pyridine-7-carbaldehydes S3



#### 1.1.1 Synthesis of nitro compound S1<sup>[1]</sup>

To a solution of 2-amino-4-methyl-3-nitropyridine (7.63 g, 49.6 mmol) in ethanol (80 mL) was added chloroacetaldehyde (40% in water) (35 mL, 178.6 mmol) slowly and the resulting mixture was refluxed at 85 °C for 9 h. After cooling to room temperature, the solvent was removed under reduced pressure and the residue was alkalized with NaHCO<sub>3</sub> (100 mL). After filtration and drying in vacuo, 7-methyl-8-nitroimidazo[1,2-a]pyridine (**S1a**)<sup>[1]</sup> was obtained as yellow solid; yield: 8.42 g (96%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.16 (d, *J* = 6.8 Hz, 1H), 7.68 (d, *J* = 1.2 Hz, 1H), 7.64 (d, *J* = 1.2 Hz, 1H), 6.73 (d, *J* = 6.8 Hz, 1H), 2.49 (s, 3H).


To a solution of 2-amino-4-methyl-3-nitropyridine (10.12 g, 65.3 mmol) in EtOH-H<sub>2</sub>O (1:1 v/v, 150 mL) was added α-bromoacetophenone (13.08 g, 65.3 mmol) slowly and the resulting mixture was refluxed at 85 °C for 9 h. After cooling to room temperature, the solvent was removed under reduced pressure and the residue was recrystallized at 0 °C. After filtration and drying in vacuo, 7-methyl-8-nitro-2-phenylimidazo[1,2-a]pyridine (**S1b**) was obtained as yellow solid; yield: 8.75 g (53%); m.p. 194.7~195.9 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.10 (d, *J* = 6.8 Hz, 1H), 9.74 (d, *J* = 7.2 Hz, 2H), 7.86 (s, 1H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.36-7.32 (m, 1H), 6.66 (d, *J* = 7.2 Hz, 1H), 2.46 (s, 3H); <sup>13</sup>C NMR (151 MHz, DMSO) δ 145.3, 137.5, 137.2, 132.8, 128.95, 128.93, 128.8, 128.3, 125.8, 114.4, 110.6, 16.8; HRMS (TOF-EI): *m/z* [M]<sup>+</sup> calcd. for C<sub>14</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup>: 253.0851; Found: 253.0853.

#### 1.1.2 General Procedure for the synthesis of nitroaldehyde compound S2

To a solution of the nitro compound **S1** (45.5 mmol) dissolved in super dry DMF (65 mL), was added DMF-DMA (7.9 mL, 68.2 mmol) under N<sub>2</sub>. The reaction mixture was heated to 130 °C for 2h. After cooling to 90 °C, the solvent and excess reactant were evaporated under reduced pressure to afford crude product as red solid that was used in the next step without further purification.


To a solution of the above-mentioned crude product in THF/H<sub>2</sub>O (1/1, v/v) (270 mL), sodium periodate (10.76 g, 50.0 mmol) was added and the reaction mixture was stirred at room temperature for 2 h. After completion, the THF was removed by evaporation and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 40 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude product was purified by flash silica gel chromatography (100~200 mesh silica gel, petroleum ether/ethyl acetate = 4:3 as eluent) to afford nitroaldehyde compound **S2**.

#### 8-Nitroimidazo[1,2-a]pyridine-7-carbaldehyde (**S2a**)<sup>[1]</sup>



General procedure was followed on **S1a** (8.12 g, 45.5 mmol) to afford **S2a**. Yellow solid; yield: 2.71 g (32%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.19 (s, 1H), 8.39 (d, *J* = 6.8 Hz, 1H), 7.99 (d, *J* = 1.2 Hz, 1H), 7.91 (d, *J* = 1.2 Hz, 1H), 7.41 (d, *J* = 7.2 Hz, 1H).

#### 8-Nitro-2-phenylimidazo[1,2-a]pyridine-7-carbaldehyde (**S2b**)




General procedure was followed on **S1b** (11.52 g, 45.5 mmol) to afford **S2b**. Orange solid; yield: 4.33 g (36%); m.p. 148.9~150.1°C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.16 (s, 1H), 8.33 (d, *J* = 7.2 Hz, 1H), 8.14 (s, 1H), 7.99 (dd, *J* = 8.0, 2.0 Hz, 2H), 7.49-7.36 (m, 4H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 184.8, 151.0, 136.6, 131.7, 129.5, 128.9, 127.5, 126.6, 122.5, 111.7, 108.5; HRMS (TOF-EI): *m/z* [M]<sup>+</sup> calcd. for C<sub>14</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup>: 267.0644; Found: 267.0642.

### 1.1.3 General Procedure for the synthesis of amino aldehyde compound **S3**


To a solution of compound **S2** (15.0 mmol) dissolved in a mixture of ethanol/water (82.5 mL, 10:1, v/v), powder of iron (4.23 g, 75.2 mmol) and NH<sub>4</sub>Cl (0.48 g, 9.1 mmol) were added. The reaction mixture was stirred at 90 °C for 3 h. After cooling at room temperature, the reaction mixture was filtered on Celite and washed by ethyl acetate, then the lower boiling point organic solvent in the filtrate was removed by evaporation under reduced pressure. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 40 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude product was purified by flash silica gel chromatography (100~200 mesh silica gel, petroleum ether/ethyl acetate = 3:2 as eluent) to afford amino aldehyde compound **S3**.

#### 8-Aminoimidazo[1,2-a]pyridine-7-carbaldehyde (**S3a**)<sup>[1]</sup>



General procedure was followed on **S2a** (2.94 g, 15.0 mmol) to afford **S3a**. Yellow solid; yield: 1.43 g (62%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.81 (s, 1H), 8.57 (br s, NH), 7.59 (d, *J* = 1.2 Hz, 1H), 7.54 (d, *J* = 1.2 Hz, 1H), 7.45 (d, *J* = 6.8 Hz, 1H), 6.84 (d, *J* = 6.8 Hz, 1H), 6.57 (br s, NH).

#### 8-Amino-2-phenylimidazo[1,2-a]pyridine-7-carbaldehyde (**S3b**)




General procedure was followed on **S2b** (4.02 g, 15.0 mmol) to afford **S3b**. Yellow solid; yield: 2.52 g (70%); m.p. 158.2~159.6 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.80 (s, 1H), 8.52 (br s, 1H), 7.92 (dt, *J* = 7.2, 1.6 Hz, 2H), 7.78 (s, 1H), 7.46-7.42 (m, 3H), 7.37-7.33 (m, 1H), 6.82 (d, *J* = 7.2 Hz, 1H), 6.52 (br s, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 191.0, 145.8, 141.3, 137.5,

133.2, 128.8, 128.1, 125.8, 114.9, 113.4, 111.4, 107.3; HRMS (TOF-EI):  $m/z$   $[M]^+$  calcd. for  $C_{14}H_{11}N_3O^+$ : 237.0902; Found: 237.0899.


## 1.2 Synthesis of 2-acetyl-imidazo[1,2-h][1,7]naphthyridines

### 1.2.1 Synthesis of 1-(2,5,5-trimethyl-1,3-dioxan-2-yl)ethan-1-one (**S4**)<sup>[2]</sup>



To a solution of 2,2-dimethylpropane-1,3-diol (2.92 g, 27.5 mmol) and  $TMSCl$  (2.72 g, 25.0 mmol) in 10 mL of  $CH_2Cl_2$  was added the solution of 2,3-butanedione (2.24 g, 25 mmol) in 30 mL of  $CH_2Cl_2$  dropwise with stirring. The resulting mixture was stirred at room temperature overnight (monitored by TLC). After completion, the reaction was quenched by addition of 20 mL of saturated  $NaHCO_3$  solution and extracted by  $CH_2Cl_2$  ( $3 \times 10$  mL). Combined the organic phase and dried over anhydrous  $Na_2SO_4$ . Filtered, concentrated, the residue was purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate = 30:1) to give compound **S4** as colorless oil; yield: 4.03 g (94%);  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  3.49 (dt,  $J = 11.6, 1.2$  Hz, 2H), 3.40 (d,  $J = 11.2$  Hz, 2H), 2.23 (s, 3H), 1.42 (s, 3H), 1.56 (s, 3H), 0.72 (s, 3H).


### 1.2.2 General procedure for the synthesis of 9-(2,5,5-trimethyl-1,3-dioxan-2-yl)imidazo[1,2-h][1,7]naphthyridines **S5**



A solution of aminoaldehyde **S3** (8.2 mmol), **S4** (1.73 g, 9.8 mmol) and  $KOH$  (23.0 mg, 0.41 mmol, 0.05 eq.) in 25 mL of  $EtOH$  was stirred at  $85^\circ C$  for 10 h. After completion, the  $EtOH$  was evaporated under reduced pressure and the residue was purified by flash silica gel


chromatograph (100~200 mesh silica gel) to give **S5**.

#### 9-(2,5,5-Trimethyl-1,3-dioxan-2-yl)imidazo[1,2-h][1,7]naphthyridine (**S5a**)




General procedure was followed on **S3a** (1.32 g, 8.2 mmol) and purified by chromatograph (using DCM:EtOH = 30:1 as eluent) to afford **S5a**. Yellow solid; yield: 2.43 g (97%); m.p. 91.3~92.5 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.07 (d, *J* = 8.4 Hz, 1H), 8.02 (d, *J* = 6.8 Hz, 1H), 7.77 (d, *J* = 8.4 Hz, 1H), 7.73 (d, *J* = 1.2 Hz, 1H), 7.65 (d, *J* = 1.2 Hz, 1H), 7.04 (d, *J* = 6.8 Hz, 1H), 3.60 (d, *J* = 10.8 Hz, 2H), 3.55 (d, *J* = 11.2 Hz, 2H), 1.72 (s, 3H), 1.26 (s, 3H), 0.64 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 161.6, 142.8, 140.1, 135.7, 132.6, 124.2, 124.0, 121.2, 114.9, 111.5, 100.2, 72.3, 29.9, 29.0, 22.9, 22.0; HRMS (TOF-EI): *m/z* [M]<sup>+</sup> calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup>: 297.1477; Found: 297.1475.

#### 2-Phenyl-9-(2,5,5-trimethyl-1,3-dioxan-2-yl)imidazo[1,2-h][1,7]naphthyridine (**S5b**)




General procedure was followed on **S3b** (1.91 g, 8.2 mmol) and purified by chromatograph (using petroleum ether: ethyl acetate = 2:1 as eluent) to afford **S5b**. Orange solid; yield: 2.71 g (90%); m.p. 100.5~102.1 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.09-8.03 (m, 4H), 7.92 (s, 1H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.45 (t, *J* = 7.2 Hz, 2H), 7.32 (t, *J* = 7.2 Hz, 1H), 7.05 (d, *J* = 7.2 Hz, 1H), 3.61 (d, *J* = 11.2 Hz, 2H), 3.55 (d, *J* = 11.2 Hz, 2H), 1.72 (s, 3H), 1.30 (s, 3H), 0.63 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 161.3, 144.9, 142.8, 139.8, 136.0, 133.0, 128.8, 128.0, 126.0, 124.2, 124.1, 121.1, 111.6, 110.6, 72.4, 30.0, 29.7, 22.8, 21.9; HRMS (TOF-EI): *m/z* [M]<sup>+</sup> calcd. for C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup>: 373.1790; Found: 373.1787.

#### 1.2.3 General procedure for the synthesis of 2-acetyl-imidazo[1,2-h][1,7]naphthyridines **S6**




A solution of **S5**, 3M HCl solution (4 mL) in 15 mL of MeOH was stirred at 70 °C for 1h. After completion, the excess of MeOH was removed by evaporation, and the residue was neutralized by addition of saturated NaHCO<sub>3</sub> solution, extracted by CH<sub>2</sub>Cl<sub>2</sub> (3×30 mL). Combined the organic phase and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtered, concentrated under reduced pressure, the residue was purified by flash silica gel chromatography (100~200 mesh silica gel) to give **S6**.

#### 1-(Imidazo[1,2-h][1,7]naphthyridin-9-yl)ethan-1-one (**S6a**)



General procedure was followed on **S5a** (2.42 g, 8.1 mmol) and purified by chromatograph (using DCM:EtOH = 30:1 as eluent) to afford **S6a**. Yellow solid; yield: 1.63 g (92%); m.p. 150.2-153.8 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.24 (d, *J* = 8.4 Hz, 1H), 8.16 (d, *J* = 8.4 Hz, 1H), 8.10 (d, *J* = 7.2 Hz, 1H), 7.78 (d, *J* = 1.2 Hz, 1H), 7.69 (d, *J* = 1.2 Hz, 1H), 7.08 (d, *J* = 7.2 Hz, 1H), 2.98 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 200.0, 153.4, 142.4, 139.6, 135.6, 133.0, 127.2, 125.7, 120.2, 115.4, 111.3, 26.0; HRMS (TOF-EI): *m/z* [M]<sup>+</sup> calcd. for C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O<sup>+</sup>: 211.0476; Found: 211.0478.


#### 1-(2-Phenylimidazo[1,2-h][1,7]naphthyridin-9-yl)ethan-1-one (**S6b**)



General procedure was followed on **S5b** (2.71 g, 7.3 mmol) and purified by chromatograph (using petroleum ether: ethyl acetate = 2:1 as eluent) to afford **S6b**. Orange solid; yield: 2.03 g


(94%); m.p. 177.8~180.1 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.24 (d, *J* = 8.0 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 8.11-8.09 (m, 3H), 7.97 (s, 1H), 7.49 (t, *J* = 7.6 Hz, 2H), 7.36 (t, *J* = 7.6 Hz, 1H), 7.09 (d, *J* = 7.2 Hz, 1H), 3.03 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 200.2, 153.5, 145.4, 142.4, 139.3, 135.8, 133.1, 128.6, 128.1, 127.3, 126.1, 125.5, 120.3, 111.3, 110.9, 26.0; HRMS (TOF-ED): *m/z* [M]<sup>+</sup> calcd. for C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>O<sup>+</sup>: 287.1059; Found: 287.1061.

### 1.3 Synthesis of 2-imino-imidazo[1,2-h][1,7]naphthyridine ligands L1-L5



General procedure: 2-Acetyl-imidazo[1,2-h][1,7]naphthyridine (**S6**, 1.0 equiv.), TsOH (0.15 equiv.) and anilines (1.2 equiv.) were added together in a Schlenk tube that was purged three times with argon and then stirred at 85 °C for 72 hours in anhydrous EtOH under argon. After completion, the solvent was removed by rotary evaporation under argon, and the residue was recrystallized by MeOH and washed with icy MeOH for three times (3 × 1 mL). After drying in vacuo, the corresponding ligands **L1**~**L5** were obtained.


(*E*)-*N*-(2,6-Dimethylphenyl)-1-(imidazo[1,2-h][1,7]naphthyridin-9-yl)ethan-1-imine (**L1**)



General procedure was followed on **S6a** (500.0 mg, 2.4 mmol), TsOH (68.5 mg, 0.36 mmol), 2,6-dimethylaniline (0.36 ml, 2.9 mmol) and anhydrous EtOH (15 mL), affording **L1** as yellow solid (470.0 mg, 64%); m.p. 153.5~155.6 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.62 (d, *J* = 8.4 Hz, 1H), 8.13 (d, *J* = 8.4 Hz, 1H), 8.06 (d, *J* = 7.2 Hz, 1H), 7.77 (d, *J* = 0.8 Hz, 1H), 7.68 (d, *J* = 1.2 Hz, 1H), 7.10 (d, *J* = 7.2 Hz, 1H), 7.08 (d, *J* = 7.6 Hz, 2H), 6.95 (t, *J* = 7.6 Hz, 1H), 2.44 (s, 3H), 2.05 (s, 6H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 167.7, 156.7, 148.7, 142.9,


139.5, 135.1, 132.8, 127.9, 125.7, 125.3, 124.6, 123.1, 120.6, 115.1, 111.6, 17.9, 16.9; HRMS (TOF-EI):  $m/z$   $[M]^+$  calcd. for  $C_{20}H_{18}N_4^+$ : 314.1531; Found: 314.1526.

(E)-N-(2,6-Diisopropylphenyl)-1-(imidazo[1,2-h][1,7]naphthyridin-9-yl)ethan-1-imine (**L2**)



General procedure was followed on **S6a** (500.0 mg, 2.4 mmol), TsOH (68.5 mg, 0.36 mmol), 2,6-diisopropylaniline (0.55 ml, 2.9 mmol) and anhydrous EtOH (15 mL), affording **L2** as yellow solid (531.0 mg, 61%); m.p. 183.2~185.1 °C;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.62 (d,  $J = 8.4$  Hz, 1H), 8.14 (d,  $J = 8.4$  Hz, 1H), 8.07 (d,  $J = 7.2$  Hz, 1H), 7.77 (s, 1H), 7.69 (s, 1H), 7.18 (d,  $J = 6.8$  Hz, 2H), 7.13-7.09 (m, 2H), 2.78 (hept,  $J = 6.8$  Hz, 2H), 2.48 (s, 3H), 1.15 (d,  $J = 6.8$  Hz, 12H);  $^{13}C$  NMR (151 MHz,  $CDCl_3$ )  $\delta$  167.5, 156.8, 146.4, 142.9, 139.6, 135.7, 135.1, 132.9, 125.7, 124.6, 123.7, 123.0, 120.7, 115.1, 111.6, 28.3, 23.2, 22.8, 17.6; HRMS (TOF-EI):  $m/z$   $[M]^+$  calcd. for  $C_{24}H_{26}N_4^+$ : 370.2157; Found: 370.2160.


(E)-N-(4-benzhydryl-2,6-diisopropylphenyl)-1-(imidazo[1,2-h][1,7]naphthyridin-9-yl)ethan-1-imine (**L3**)



General procedure was followed on **S6a** (500.0 mg, 2.4 mmol), TsOH (68.5 mg, 0.36 mmol), 4-benzhydryl-2,6-diisopropylaniline (996.0 mg, 2.9 mmol) and anhydrous EtOH (15 mL), affording **L3** as yellow solid (620.0 mg, 49%). m.p. 195.9~197.4 °C;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.61 (d,  $J = 8.4$  Hz, 1H), 8.13 (d,  $J = 8.4$  Hz, 1H), 8.07 (d,  $J = 7.2$  Hz, 1H), 7.77 (d,  $J = 1.2$  Hz, 1H), 7.69 (d,  $J = 1.2$  Hz, 1H), 7.32-7.28 (m, 4H), 7.24-7.20 (m, 2H), 7.18-7.16 (m, 4H), 7.10 (d,  $J = 7.2$  Hz, 1H), 6.91 (s, 2H), 5.54 (s, 1H), 2.73 (hept,  $J = 6.8$  Hz, 2H), 2.49 (s,


3H), 1.06 (d,  $J = 6.8$  Hz, 6H), 1.03 (d,  $J = 6.8$  Hz, 6H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  167.6, 156.8, 144.7, 144.5, 143.0, 139.6, 138.6, 135.4, 135.1, 133.0, 129.5, 128.1, 126.0, 125.7, 124.6, 124.3, 120.7, 115.1, 111.6, 56.9, 28.3, 23.2, 22.9, 17.7; HRMS (TOF-EI):  $m/z$   $[\text{M}]^+$  calcd. for  $\text{C}_{37}\text{H}_{36}\text{N}_4^+$ : 536.2940; Found: 536.2939.

(E)-N-(4-bromo-2,6-diisopropylphenyl)-1-(imidazo[1,2-h][1,7]naphthyridin-9-yl)ethan-1-imine (**L4**)



General procedure was followed on **S6a** (500.0 mg, 2.4 mmol), TsOH (68.5 mg, 0.36 mmol), 4-bromo-2,6-diisopropylaniline (0.6 mL, 2.9 mmol) and anhydrous EtOH (15 mL), affording **L4** as yellow solid (511.0 mg, 49%). m.p. 207.2~208.7 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.57 (d,  $J = 8.8$  Hz, 1H), 8.14 (d,  $J = 8.8$  Hz, 1H), 8.07 (d,  $J = 6.4$  Hz, 1H), 7.77 (s, 1H), 7.69 (s, 1H), 7.26 (s, 2H), 7.11 (d,  $J = 6.8$  Hz, 1H), 2.76-2.70 (m, 2H), 2.47 (s, 3H), 1.13 (d,  $J = 6.4$  Hz, 12H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  168.2, 156.5, 145.5, 142.9, 139.6, 133.0, 126.3, 125.8, 124.8, 120.6, 117.0, 115.1, 111.6, 28.4, 23.0, 22.6, 17.7; HRMS (TOF-EI):  $m/z$   $[\text{M}]^+$  calcd. for  $\text{C}_{24}\text{H}_{25}\text{BrN}_4^+$ :448.1263; Found: 448.1259.

(E)-N-(2,6-Diisopropylphenyl)-1-(2-phenylimidazo[1,2-h][1,7]naphthyridin-9-yl)ethan-1-imine (**L5**)




General procedure was followed on **S6b** (500.0 mg, 1.7 mmol), TsOH (49.5 mg, 0.26 mmol), 2,6-diisopropylaniline (0.38 mL, 2.04 mmol) and anhydrous EtOH (15 mL), affording **L5** as yellow solid (500.0 mg, 65%). m.p. 257.1~258.7 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.65

(d,  $J = 8.4$  Hz, 1H), 8.16-8.07 (m, 4H), 7.98 (s, 1H), 7.46 (t,  $J = 7.6$  Hz, 2H), 7.34 (t,  $J = 7.2$  Hz, 1H), 7.19 (d,  $J = 7.6$  Hz, 2H), 7.12 (d,  $J = 7.2$  Hz, 2H), 2.84-2.74 (m, 2H), 2.53 (s, 3H), 1.17 (d,  $J = 2.8$  Hz, 6H), 1.15 (d,  $J = 2.8$  Hz, 6H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  167.4, 156.7, 146.4, 145.3, 142.9, 139.3, 135.7, 135.2, 133.3, 128.6, 127.9, 126.2, 125.9, 124.5, 123.7, 123.0, 120.8, 111.7, 110.7, 28.3, 23.2, 22.9, 17.5; HRMS (TOF-ESI):  $m/z$   $[\text{M}]^+$  calcd. for  $\text{C}_{30}\text{H}_{30}\text{N}_4^+$ : 446.2470; Found: 446.2466.


## 2. Synthesis of Nickel Complexes Ni1-Ni5 and Ni3-Al

### 2.1 Synthesis of Nickel Complexes Ni1-Ni5




General procedure:  $\text{DME}\cdot\text{NiCl}_2$  and ligand **L1-L5** were added together in a Schlenk tube that was purged three times with argon and then stirred at room temperature for 9 hours in super dry EtOH under argon. After completion, the solvent was removed by filtration under argon, and the residue was washed with  $\text{Et}_2\text{O}$  for three times ( $3 \times 5$  mL). After drying in vacuo, the corresponding nickel complexes **Ni1-Ni5** were obtained.

Nickel complex **Ni1**:




General procedure was followed on **L1** (200.0 mg, 0.62 mmol),  $\text{DME}\cdot\text{NiCl}_2$  (123.0 mg, 0.56 mmol) and super dry EtOH (6 mL), affording **Ni1** as yellow solid (161.0 mg, 57%). Anal. Calcd. for  $\text{C}_{20}\text{H}_{18}\text{Cl}_2\text{N}_4\text{Ni}\cdot 0.5$  EtOH (%): C, 54.01; H, 4.53; N, 12.00; Found: C, 53.70; H, 4.13; N, 12.18.

Nickle complex **Ni2**:




General procedure was followed on **L2** (100.0 mg, 0.27 mmol), DME·NiCl<sub>2</sub> (54.9 mg, 0.25 mmol) and super dry EtOH (5 mL), affording **Ni2** as yellow solid (69.2 mg, 51%). Anal. Calcd. for C<sub>24</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>4</sub>Ni·0.5 EtOH (%): C, 57.40; H, 5.59; N, 10.71; Found: C, 57.24; H, 5.16; N, 10.98.

Nickle complex **Ni3**:




General procedure was followed on **L3** (200.0 mg, 0.37 mmol), DME·NiCl<sub>2</sub> (90.1 mg, 0.41 mmol) and super dry EtOH (6 mL), affording **Ni3** as yellow solid (104.7 mg, 42%). Anal. Calcd. for C<sub>37</sub>H<sub>36</sub>Cl<sub>2</sub>N<sub>4</sub>Ni·H<sub>2</sub>O (%): C, 64.94; H, 5.60; N, 8.19; Found: C, 64.95; H, 5.58; N, 7.90.

Nickle complex **Ni4**:



General procedure was followed on **L4** (200.0 mg, 0.45 mmol), DME·NiCl<sub>2</sub> (110.0 mg, 0.50 mmol) and super dry EtOH (6 mL), affording **Ni4** as yellow solid (153.2 mg, 59%). Anal. Calcd. for C<sub>24</sub>H<sub>25</sub>BrCl<sub>2</sub>N<sub>4</sub>Ni·0.5 H<sub>2</sub>O (%): C, 49.02; H, 4.46; N, 9.53; Found: C, 49.36; H, 4.14; N, 9.15.

Nickle complex **Ni5**:



General procedure was followed on **L5** (100.0 mg, 0.22 mmol), DME·NiCl<sub>2</sub> (39.5 mg, 0.18 mmol) and super dry EtOH (5 mL), affording **Ni5** as yellow solid (77.1 mg, 60%). Anal. Calcd. for C<sub>30</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>4</sub>Ni·0.5 EtOH (%): C, 62.14; H, 5.55; N, 9.35; Found: C, 62.11; H, 5.2; N, 9.45.

## 2.2 Synthesis of Nickel Complexes Ni3-Al

Inside a glovebox, complex **Ni3** (60 mg, 0.09 mmol), PPh<sub>3</sub> (236 mg, 0.9 mmol), 18 mL of THF, and 12 mL of diethyl ether were charged into a 50 mL Schlenk tube. The mixture was stirred at room temperature for 30 min, followed by the dropwise addition of Et<sub>2</sub>AlCl (0.9 mL, 0.9 mmol, 1 M in toluene). After stirring for an additional 10 min, the resulting mixture was filtered to afford a pale-yellow solution. n-Hexane (10 mL) was slowly added along the wall, and the solution was maintained at -40 °C for recrystallization over 72 h. The crystalline solid was collected by filtration and washed with cold n-hexane, affording yellow crystals of the **Ni3-Al** complex ([**L3**·NiCl(THF)<sub>2</sub>]<sup>+</sup>·EtAlCl<sub>3</sub><sup>-</sup>) (23 mg, 27%). Anal. Calc for C<sub>47</sub>H<sub>57</sub>AlCl<sub>4</sub>N<sub>4</sub>NiO<sub>2</sub>·H<sub>2</sub>O: C, 59.08; H, 6.22; N, 5.86. Found: C, 59.00; H, 6.25; N, 5.48.

## 3. Oligomerization of ethylene: General procedure

Before the reaction, a 250 mL stainless-steel reactor was dried at 120 °C under vacuum for 3 h, cooled down to the desired reaction temperature and then recharged with ethylene three times. The nickel complex catalyst was first weighed into a Schlenk vessel under nitrogen; then, toluene and cocatalyst were added into the Schlenk vessel in turn. The resulting mixture was stirred for 1 min and immediately added to the stainless-steel reactor. Then, the reactor was immediately pressurized. After the specified reaction time, the reaction was stopped by shutting in the ethylene feed. The reaction system was cooled to around -20 °C, depressurized, and

quenched by the addition of 30 mL of 10% aq. HCl solution. A small sample of the upper-layer solution was filtered through a layer of Celite and analyzed by GC using nonane as the internal standard. The individual oligomerization products were identified by GC-MS.

#### References:

- [1] Andaloussi, M.; Moreau, E.; Masurier, N.; Lacroix, J.; Gaudreault, R. C.; Chezal, J.-M.; El Laghdach, A.; Canitrot, D.; Debiton, E.; Teulade, J.-C.; Chavignon, O. Novel imidazo[1,2-a]naphthyridinic systems (part 1): Synthesis, antiproliferative and DNA-intercalating activities. *Eur. J. Med. Chem.* **2008**, *43*, 2505-2517.
- [2] Levine, S. G.; Mauney, C. U. Facile preparation of a butane-2,3-dione monoketal. *Synth. Commun.* **1988**, *18*, 689-691.

#### 4. X-Ray Crystallography for Nickel Complexes

Crystallization procedures of Nickel complexes **Ni1–Ni3** and **Ni5**: Single crystals of **Ni1–Ni3** and **Ni5** suitable for single-crystal X-ray diffraction were grown by slow diffusion of diethyl ether (4.0 mL) into a DMF solution (0.5 mL) of nickel complexes **Ni1–Ni3** or **Ni5** (20 mg) in a dried Schlenk tube under an argon atmosphere.

Crystallization procedure of Nickel complex **Ni3-Al**: In a glovebox, PPh<sub>3</sub> (78 mg, 300 μmol) was added to a solution of complex **Ni3** (20 mg, 30 μmol) in 10 mL of THF/Et<sub>2</sub>O (3:2 v/v). After stirring at room temperature for 30 min, Et<sub>2</sub>AlCl (0.3 mL, 300 μmol, 1 M in toluene) was added. The resulting mixture was stirred for another 10 min, and then filtered to obtain a pale-yellow solution. Single crystal of **Ni3–Al** suitable for single-crystal X-ray diffraction was grown by slowly diffusing n-hexane (5 mL) into the above solution at -40 °C in a dried Schlenk tube under an argon atmosphere.

All of these crystals were mounted on a glass fiber. Crystallographic measurements were made on a Bruker APEX-II CCD area detector using graphite monochromated Cu-K $\alpha$  radiation ( $\lambda_{\text{Cu-K}\alpha} = 1.54178 \text{ \AA}$ ). Refinements and reductions of the collected data were achieved using the Bruker SAINT program and applied to all complexes with absorption correction (multi-scan). The structures were solved by directed methods and refined on F<sup>2</sup> by the full-matrix least-squares techniques with the SHELXTL-2016 program.

Key details of the crystals and structure refinement data are summarized in Table S1-S5. Further crystallographic details may be found in the respective CIF files, which were deposited at the Cambridge Crystallographic Data Centre, Cambridge, UK.

**Table S1 Crystal data and structure refinement for Ni1.**

CCDC No.	2542431
Empirical formula	C <sub>23</sub> H <sub>25</sub> Cl <sub>2</sub> N <sub>5</sub> NiO
Formula weight	517.09
Temperature/K	290.0
Crystal system	triclinic
Space group	P-1
a/Å	10.4692(2)
b/Å	11.8245(2)
c/Å	13.6613(2)
α/°	65.2764(9)
β/°	82.8550(9)
γ/°	65.3355(9)
Volume/Å <sup>3</sup>	1393.43(4)
Z	2
ρ <sub>calc</sub> /cm <sup>3</sup>	1.232
μ/mm <sup>-1</sup>	2.941
F(000)	536.0
Crystal size/mm <sup>3</sup>	0.1 × 0.1 × 0.1
Radiation	CuKα (λ = 1.54178)
2θ range for data collection/°	7.136 to 149.396
Index ranges	-13 ≤ h ≤ 12, -14 ≤ k ≤ 14, -17 ≤ l ≤ 16
Reflections collected	19502
Independent reflections	5581 [R <sub>int</sub> = 0.0322, R <sub>sigma</sub> = 0.0321]
Data/restraints/parameters	5581/1/313
Goodness-of-fit on F <sup>2</sup>	1.078
Final R indexes [I >= 2σ (I)]	R <sub>1</sub> = 0.0419, wR <sub>2</sub> = 0.1209
Final R indexes [all data]	R <sub>1</sub> = 0.0443, wR <sub>2</sub> = 0.1228
Largest diff. peak/hole / e Å <sup>-3</sup>	0.34/-0.40

**Table S2 Crystal data and structure refinement for Ni2.**

CCDC No.	2542445
Empirical formula	C <sub>24</sub> H <sub>26</sub> Cl <sub>2</sub> N <sub>4</sub> Ni
Formula weight	500.10
Temperature/K	200.00
Crystal system	orthorhombic
Space group	Pbca
a/Å	14.6615(2)
b/Å	15.7274(3)
c/Å	19.5070(3)
α/°	90
β/°	90
γ/°	90
Volume/Å <sup>3</sup>	4498.07(13)
Z	8
ρ <sub>calc</sub> /g/cm <sup>3</sup>	1.477
μ/mm <sup>-1</sup>	3.576
F(000)	2080.0
Crystal size/mm <sup>3</sup>	0.04 × 0.03 × 0.015
Radiation	CuKα (λ = 1.54178)
2θ range for data collection/°	9.41 to 149.074
Index ranges	-18 ≤ h ≤ 17, -19 ≤ k ≤ 14, -23 ≤ l ≤ 23
Reflections collected	39760
Independent reflections	4590 [R <sub>int</sub> = 0.0580, R <sub>sigma</sub> = 0.0281]
Data/restraints/parameters	4590/0/285
Goodness-of-fit on F <sup>2</sup>	1.030
Final R indexes [I ≥ 2σ (I)]	R <sub>1</sub> = 0.0367, wR <sub>2</sub> = 0.0935
Final R indexes [all data]	R <sub>1</sub> = 0.0446, wR <sub>2</sub> = 0.0981
Largest diff. peak/hole / e Å <sup>-3</sup>	0.91/-0.31

**Table S3 Crystal data and structure refinement for Ni3.**

CCDC No.	2542441
Empirical formula	C <sub>40</sub> H <sub>43</sub> Cl <sub>2</sub> N <sub>5</sub> NiO
Formula weight	739.40
Temperature/K	200.0
Crystal system	triclinic
Space group	P-1
a/Å	9.8014(2)
b/Å	15.5910(3)
c/Å	16.5325(3)
α/°	116.0100(10)
β/°	92.7180(10)
γ/°	105.9430(10)
Volume/Å <sup>3</sup>	2141.58(7)
Z	2
ρ <sub>calc</sub> /g/cm <sup>3</sup>	1.147
μ/mm <sup>-1</sup>	2.058
F(000)	776.0
Crystal size/mm <sup>3</sup>	0.05 × 0.01 × 0.01
Radiation	CuKα (λ = 1.54178)
2Θ range for data collection/°	6.68 to 149.766
Index ranges	-12 ≤ h ≤ 12, -17 ≤ k ≤ 19, -20 ≤ l ≤ 20
Reflections collected	44850
Independent reflections	8765 [R <sub>int</sub> = 0.0489, R <sub>sigma</sub> = 0.0327]
Data/restraints/parameters	8765/7/485
Goodness-of-fit on F <sup>2</sup>	1.069
Final R indexes [I ≥ 2σ (I)]	R <sub>1</sub> = 0.0335, wR <sub>2</sub> = 0.0912
Final R indexes [all data]	R <sub>1</sub> = 0.0410, wR <sub>2</sub> = 0.0951
Largest diff. peak/hole / e Å <sup>-3</sup>	0.27/-0.33

**Table S4 Crystal data and structure refinement for Ni5.**


CCDC No.	2542434
Empirical formula	C <sub>33</sub> H <sub>37</sub> Cl <sub>2</sub> N <sub>5</sub> NiO
Formula weight	649.28
Temperature/K	200.0
Crystal system	monoclinic
Space group	P2 <sub>1</sub> /c
a/Å	12.9309(2)
b/Å	13.2937(2)
c/Å	19.3267(4)
α/°	90
β/°	100.2736(9)
γ/°	90
Volume/Å <sup>3</sup>	3268.99(10)
Z	4
ρ <sub>calc</sub> /g/cm <sup>3</sup>	1.319
μ/mm <sup>-1</sup>	2.619
F(000)	1360.0
Crystal size/mm <sup>3</sup>	0.1 × 0.1 × 0.1
Radiation	CuKα (λ = 1.54178)
2Θ range for data collection/°	6.948 to 149.406
Index ranges	-15 ≤ h ≤ 15, -15 ≤ k ≤ 16, -24 ≤ l ≤ 23
Reflections collected	41821
Independent reflections	6654 [R <sub>int</sub> = 0.0373, R <sub>sigma</sub> = 0.0254]
Data/restraints/parameters	6654/0/386
Goodness-of-fit on F <sup>2</sup>	1.082
Final R indexes [I ≥ 2σ (I)]	R <sub>1</sub> = 0.0420, wR <sub>2</sub> = 0.1209
Final R indexes [all data]	R <sub>1</sub> = 0.0453, wR <sub>2</sub> = 0.1233
Largest diff. peak/hole / e Å <sup>-3</sup>	0.53/-0.52

**Table S5 Crystal data and structure refinement for Ni3-Al.**

CCDC No.	2542443
Empirical formula	C <sub>51</sub> H <sub>64</sub> AlCl <sub>4</sub> N <sub>4</sub> NiO <sub>3</sub>
Formula weight	1008.55
Temperature/K	150.00
Crystal system	triclinic
Space group	P-1
a/Å	13.6838(5)
b/Å	14.2840(5)
c/Å	16.1028(6)
α/°	101.275(2)
β/°	90.059(2)
γ/°	108.916(2)
Volume/Å <sup>3</sup>	2912.95(19)
Z	2
ρ <sub>calc</sub> /g/cm <sup>3</sup>	1.150
μ/mm <sup>-1</sup>	2.621
F(000)	1062.0
Crystal size/mm <sup>3</sup>	0.07 × 0.04 × 0.03
Radiation	CuKα (λ = 1.54178)
2Θ range for data collection/°	5.61 to 150.334
Index ranges	-17 ≤ h ≤ 17, -15 ≤ k ≤ 17, -20 ≤ l ≤ 20
Reflections collected	50560
Independent reflections	11858 [R <sub>int</sub> = 0.0569, R <sub>sigma</sub> = 0.0520]
Data/restraints/parameters	11858/12/605
Goodness-of-fit on F <sup>2</sup>	1.085
Final R indexes [I ≥ 2σ (I)]	R <sub>1</sub> = 0.0508, wR <sub>2</sub> = 0.1484
Final R indexes [all data]	R <sub>1</sub> = 0.0614, wR <sub>2</sub> = 0.1570
Largest diff. peak/hole / e Å <sup>-3</sup>	0.44/-0.72

## 5. Gas chromatograms (GC) of the oligomers


Quantitative gas chromatographic analysis of the products of oligomerization was performed on a Shimadzu GC 2014 Series GC instrument with a J&W DB-1 column working at 30 °C for 10 min and then heating at 10 °C min<sup>-1</sup> until 280 °C. n-Nonane was used as an internal standard.



DET#1

Peak No	Ret. Time (min)	Peak height	Area (counts)	Area (%)	SepCode
1	4.439	245807	569926	0.1129	
2	4.515	22158910	65803324	12.9659	SV
3	5.069	363796	1124589	0.2229	T
4	5.161	313041	1492983	0.2949	TV
5	8.493	9787744	396355228	78.0919	SV
6	8.903	22857	64177	0.0139	T
7	12.087	9261	51052	0.0109	T
8	12.343	16344	82994	0.0169	TV
9	13.923	2420827	40484420	7.9769	
10	16.321	6945	41329	0.0089	
11	34.876	72644	777321	0.1539	
12	41.861	33228	531472	0.1059	
13	42.927	1801	58797	0.0129	V
14	44.218	1976	114859	0.0239	V
Total		35455182	507552471	100.0009	


**Figure S1** GC trace and data for oligomers produced with complex Ni3/Et<sub>2</sub>AlCl at 20 °C and 3.0 MPa of ethylene pressure (Table 3, entry 12)



DET#1

Peak No	Ret. Time (min)	Peak height	Area (counts)	Area (%)	SepCode
1	4.533	21069905	81925479	26.8529	S
2	4.903	202158	528172	0.1739	T
3	5.066	217547	517591	0.1709	T
4	5.159	1048342	4637410	1.5209	TV
5	5.229	251661	946723	0.3109	TV
6	8.030	6633177	158569630	51.9729	SV
7	8.606	12981	56006	0.0189	T
8	9.014	8287	41005	0.0139	T
9	12.028	10786	68013	0.0229	
10	12.289	18347	124884	0.0419	V
11	13.986	2893324	57116111	18.7209	
12	39.844	11684	275588	0.0909	
13	41.600	1417	79605	0.0269	V
14	44.202	1976	217947	0.0719	V
Total		32381593	305104163	100.0009	

**Figure S2** GC trace and data for oligomers produced with complex  $\text{Ni3}/\text{Et}_2\text{AlCl}/\text{PPh}_3$  (10 equiv.) at 20 °C and 3.0 MPa of ethylene pressure (Table 4, entry 6)




DET#1

Peak No	Ret. Time (min)	Peak height	Area (counts)	Area (%)	SepCode
1	4.555	8727511	29321301	35.0869	S
2	4.915	46893	120407	0.1449	T
3	5.079	13399	29565	0.0359	T
4	5.169	200873	875934	1.0489	TV
5	5.241	71544	247669	0.2969	TV
6	7.674	3637323	41924884	50.4689	
7	13.597	1097102	10097168	12.0829	
8	17.938	474	41979	0.0509	
9	37.761	1387	159713	0.1919	
10	37.991	1483	61035	0.0739	V
11	43.266	4732	610018	0.7309	V
12	43.817	2540	80500	0.0969	V
Total		13805261	83570173	100.0009	


**Figure S3** GC trace and data for oligomers produced with complex **Ni3-Al**/Et<sub>2</sub>AlCl/PPh<sub>3</sub> (10 equiv.) at 20 °C and 3.0 MPa of ethylene pressure (Table 4, entry 9)

## 6. NMR spectrum of Compounds S1-S6 and L1-L5


$^1\text{H}$  NMR of S1a (400 M,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR of S1b (400 M,  $\text{CDCl}_3$ )




### <sup>13</sup>C NMR of S1b (151 M, DMSO)




### <sup>1</sup>H NMR of S2a (400 M, CDCl<sub>3</sub>)




### <sup>1</sup>H NMR of S2b (400 M, CDCl<sub>3</sub>)




### <sup>13</sup>C NMR of S2b (151 M, CDCl<sub>3</sub>)




<sup>1</sup>H NMR of **S3a** (400 M, CDCl<sub>3</sub>)




<sup>1</sup>H NMR of **S3b** (400 M, CDCl<sub>3</sub>)




<sup>13</sup>C NMR of S3b (151 M, CDCl<sub>3</sub>)




<sup>1</sup>H NMR of S4 (400 M, CDCl<sub>3</sub>)




<sup>1</sup>H NMR of S5a (400 M, CDCl<sub>3</sub>)




<sup>13</sup>C NMR of S5a (151 M, CDCl<sub>3</sub>)




<sup>1</sup>H NMR of **S5b** (400 M, CDCl<sub>3</sub>)




<sup>13</sup>C NMR of **S5b** (151 M, CDCl<sub>3</sub>)




<sup>1</sup>H NMR of S6a (400 M, CDCl<sub>3</sub>)




<sup>13</sup>C NMR of S6a (151 M, CDCl<sub>3</sub>)




<sup>1</sup>H NMR of **S6b** (400 M, CDCl<sub>3</sub>)




<sup>13</sup>C NMR of **S6b** (151 M, CDCl<sub>3</sub>)




### $^1\text{H}$ NMR of L1 (400 M, $\text{CDCl}_3$ )




### $^{13}\text{C}$ NMR of L1 (101 M, $\text{CDCl}_3$ )




### <sup>1</sup>H NMR of L2 (400 M, CDCl<sub>3</sub>)




### <sup>13</sup>C NMR of L2 (151 M, CDCl<sub>3</sub>)




### <sup>1</sup>H NMR of L3 (400 M, CDCl<sub>3</sub>)




### <sup>13</sup>C NMR of L3 (151 M, CDCl<sub>3</sub>)




### $^1\text{H}$ NMR of L4 (400 M, $\text{CDCl}_3$ )



### $^{13}\text{C}$ NMR of L4 (151 M, $\text{CDCl}_3$ )



### $^1\text{H}$ NMR of **L5** (400 M, $\text{CDCl}_3$ )



### $^{13}\text{C}$ NMR of **L5** (151 M, $\text{CDCl}_3$ )

